Want to join the conversation?
$MRK narrowed its FY16 GAAP EPS guidance to range of $1.98-2.08 from prior forecast of $1.96-2.23. This reflects impact of intangible asset impairment charges and higher restructuring costs incurred in 2Q16. $MRK raised bottom end of FY16 non-GAAP EPS outlook to $3.67-3.77 from prior range of $3.65-3.77.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.